Paik, Paul K.

Publications

Sort by

Co-Author Network

selected publications

COVID-19 in patients with lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2020 Academic Article GET IT
Times cited: 196
A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 8
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2019 Academic Article GET IT
Times cited: 5
A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute. 2019 Academic Article GET IT
Times cited: 98
New Treatment Options in Advanced Squamous Cell Lung Cancer. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2019 Information Resource GET IT
Liquid biopsy guided precision therapy for lung cancers. Journal of thoracic disease. 2018 Editorial Article GET IT
Times cited: 3
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 242
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America. 2018 Academic Article GET IT
Times cited: 42
Identifying the Optimal Radiation Dose in Locally Advanced Non-Small-cell Lung Cancer Treated With Definitive Radiotherapy Without Concurrent Chemotherapy. Clinical lung cancer. 2017 Academic Article GET IT
Times cited: 11
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 112
OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 1655
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer discovery. 2017 Academic Article GET IT
Times cited: 490
Missing the mark in FGFR1-amplified squamous cell cancer of the lung. Cancer. 2016 Editorial Article GET IT
Times cited: 5
Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 356
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer discovery. 2015 Academic Article GET IT
Times cited: 490
Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer discovery. 2015 Academic Article GET IT
Times cited: 123
Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Information Resource GET IT
Times cited: 10
Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2014 Academic Article GET IT
Times cited: 106
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nature medicine. 2014 Academic Article GET IT
Times cited: 241
Discontinuous anchoring transition and photothermal switching in composites of liquid crystals and conducting polymer nanofibers. Physical review. E, Statistical, nonlinear, and soft matter physics. 2014 Academic Article GET IT
Times cited: 14
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 114
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer chemotherapy and pharmacology. 2013 Academic Article GET IT
Times cited: 14
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Academic Article GET IT
Times cited: 290
Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. The Lancet. Oncology. 2012 Information Resource GET IT
Times cited: 142
Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 516
Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012 Academic Article GET IT
Times cited: 3206
Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component. Molecular cancer therapeutics. 2012 Academic Article GET IT
Times cited: 44
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas. Cancer. 2012 Academic Article GET IT
Times cited: 126
Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 408
Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas. Cancer. 2012 Academic Article GET IT
Times cited: 49
Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 329
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Molecular cancer therapeutics. 2011 Academic Article GET IT
Times cited: 182
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2011 Academic Article GET IT
Times cited: 86
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 604
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion. Cancer chemotherapy and pharmacology. 2011 Academic Article GET IT
Times cited: 27
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies. Cancer chemotherapy and pharmacology. 2010 Academic Article GET IT
Times cited: 67
Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2010 Information Resource GET IT
Times cited: 58
IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity. 2006 Academic Article GET IT
Times cited: 290
Selective regulation of IL-10 signaling and function by zymosan. Journal of immunology (Baltimore, Md. : 1950). 2006 Academic Article GET IT
Times cited: 41
Diagnosis and management of adult onset Still's disease. Annals of the rheumatic diseases. 2005 Information Resource GET IT
Times cited: 320
Amplification of IFN-alpha-induced STAT1 activation and inflammatory function by Syk and ITAM-containing adaptors. Nature immunology. 2004 Academic Article GET IT
Times cited: 76
The oncogenic 70Z Cbl mutation blocks the phosphotyrosine binding domain-dependent negative regulation of ZAP-70 by c-Cbl in Jurkat T cells. Molecular and cellular biology. 1999 Academic Article GET IT
Times cited: 26
Activation of nuclear factor of activated T cells-(NFAT) and activating protein 1 (AP-1) by oncogenic 70Z Cbl requires an intact phosphotyrosine binding domain but not Crk(L) or p85 phosphatidylinositol 3-kinase association. The Journal of biological chemistry. 1999 Academic Article GET IT
Times cited: 27

more ...

less ...

Background

education and training

M.D., Weill Cornell Medical College, Cornell University 2005
B.S., Yale University 2000

Contact

full name

Paul K. Paik

VIVO Weill Cornell Medical College

Paul K. Paik Associate Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name